Table 1.
Baseline characteristics of the R/R multiple myeloma patients with or without extramedullary disease.
| Pt | Sex | Age (years) | KPS | Subtype | ISS stage | MM cells in the BM, % | Bone lesions | Extramedullary disease | Time to diagnosis of extramedullary disease (months) | High-risk cytogenetic lesions | Lines of prior therapy | Previous BCMA CAR T cell therapy (Murine BCMA CAR T) | Previous auto-HSCT | BCMA expression in MM cells (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| With extramedullary disease | ||||||||||||||
| 1 | Male | 57 | 90 | κ light chain | III | 86.0% | Yes | EM-B/EM-E | 5 | t(4;14), t(14;16), Del(17p) | 14 | No | Yes | 92.53 |
| 2 | Female | 71 | 100 | IgG-κ | II | 55.3% | Yes | EM-B/EM-E | 14 | Del(17p),t(4;14) | 10 | Yes | No | 94.39 |
| 3 | Male | 59 | 100 | κ light chain | III | 17.0% | Yes | EM-B/EM-E | 9 | t(14,16) | 7 | Yes | No | 81.82 |
| 4 | Male | 73 | 90 | IgD-λ | II | 23.04% | Yes | EM-E | 3 | None | 12 | No | No | 94.39 |
| 5 | Female | 38 | 90 | κ light chain | II | 70.44% | Yes | EM-B/EM-E | 6 | None | 17 | No | Yes | 93.18 |
| 6 | Male | 56 | 80 | IgG-κ | II | 32.26% | Yes | EM-B/EM-E | 5 | None | 10 | No | No | 80.26 |
| 7 | Female | 58 | 90 | IgG-λ | III | 88.12% | Yes | EM-E | 12 | None | 30 | No | No | 93.68 |
| Without extramedullary disease | ||||||||||||||
| 1 | Female | 70 | 100 | IgG-κ | II | 32.56% | Yes | - | - | Del(17p), t(4;14) | 10 | No | No | 94.76 |
| 2 | Male | 58 | 100 | κ light chain | III | 41.75% | Yes | - | - | t(14,16) | 7 | No | No | 92.57 |
| 3 | Male | 63 | 80 | IgG-κ | III | 35.62% | Yes | - | - | t(14,16) | 5 | No | Yes | 97.84 |
| 4 | Male | 66 | 100 | IgA-κ | II | 19.2% | Yes | - | - | t(14;16), Del(17p) | 16 | No | No | 90.99 |
| 5 | Female | 55 | 90 | IgG-λ | II | 44.28% | No | - | - | None | 7 | No | No | 90.41 |
| 6 | Female | 52 | 90 | IgA-λ | II | 20.72% | Yes | - | - | None | 9 | No | No | 82.93 |
| 7 | Female | 72 | 100 | Nonsecretory | II | 28.98% | Yes | - | - | None | 6 | No | No | 95.70 |
| 8 | Female | 77 | 90 | IgD-κ | III | 66.8% | Yes | - | - | None | 13 | No | No | 97.06 |
| 9 | Female | 42 | 100 | IgG-κ | III | 22.14% | Yes | - | - | t(14;16) | 5 | No | No | 96.24 |
| 10 | Female | 45 | 90 | IgG-κ | I | 19.44% | Yes | - | - | None | 5 | No | No | 82.73 |
| 11 | Female | 46 | 90 | IgG-κ | III | 22.23% | Yes | - | - | None | 7 | No | No | 88.83 |
| 12 | Male | 54 | 90 | IgG-κ | III | 17.5% | Yes | - | - | None | 8 | No | No | 92.31 |
| 13 | Male | 54 | 80 | IgG-λ | II | 14.8% | Yes | - | - | t(14;16) | 9 | No | Yes | 88.16 |
Pt, Patient; KPS, Karnofsky performance scale; ISS, international staging system; MM, multiple myeloma; BM, bone marrow; BMCA, B cell maturation antigen; CAR, chimeric antigen receptor; auto-HSCT, autologous haematopoietic stem cell transplantation; EM-B, extramedullary-bone related; EM-E, extramedullary-extraosseou.
Extramedullary-extraosseous (EM-E): Hematogenous dissemination leads to soft tissue tumors at the anatomical site far from the bone.
Extramedullary-bone related (EM-B): Breaks through the bone cortex and only invade the surrounding soft tissues.